Wagner Wealth Management LLC Reduces Stake in Johnson & Johnson (NYSE:JNJ)

by · The Cerbat Gem

Wagner Wealth Management LLC decreased its stake in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 4.4% during the third quarter, according to its most recent filing with the SEC. The institutional investor owned 4,362 shares of the company’s stock after selling 200 shares during the period. Wagner Wealth Management LLC’s holdings in Johnson & Johnson were worth $707,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in the stock. Sunflower Bank N.A. raised its holdings in shares of Johnson & Johnson by 2.2% in the 3rd quarter. Sunflower Bank N.A. now owns 10,328 shares of the company’s stock valued at $1,674,000 after acquiring an additional 219 shares in the last quarter. Compagnie Lombard Odier SCmA grew its position in shares of Johnson & Johnson by 7.1% in the 3rd quarter. Compagnie Lombard Odier SCmA now owns 286,231 shares of the company’s stock worth $46,387,000 after buying an additional 19,077 shares during the last quarter. Douglas Lane & Associates LLC grew its position in shares of Johnson & Johnson by 2.7% in the 3rd quarter. Douglas Lane & Associates LLC now owns 592,860 shares of the company’s stock worth $96,079,000 after buying an additional 15,508 shares during the last quarter. CVA Family Office LLC grew its position in shares of Johnson & Johnson by 36.9% in the 3rd quarter. CVA Family Office LLC now owns 9,116 shares of the company’s stock worth $1,477,000 after buying an additional 2,459 shares during the last quarter. Finally, Gilman Hill Asset Management LLC lifted its stake in shares of Johnson & Johnson by 18.1% in the 3rd quarter. Gilman Hill Asset Management LLC now owns 14,341 shares of the company’s stock valued at $2,324,000 after purchasing an additional 2,195 shares during the period. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Insiders Place Their Bets

In related news, VP Robert J. Decker sold 5,635 shares of Johnson & Johnson stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $165.06, for a total value of $930,113.10. Following the completion of the transaction, the vice president now owns 18,973 shares in the company, valued at $3,131,683.38. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.16% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the company. Morgan Stanley raised their target price on Johnson & Johnson from $167.00 to $169.00 and gave the company an “equal weight” rating in a research note on Thursday, July 18th. Sanford C. Bernstein lifted their price objective on Johnson & Johnson from $161.00 to $171.00 in a research note on Thursday, July 18th. TD Cowen lowered their price objective on Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating for the company in a research note on Thursday, July 18th. Daiwa Capital Markets cut Johnson & Johnson from an “outperform” rating to a “neutral” rating and lowered their price objective for the company from $160.00 to $150.00 in a research note on Tuesday, July 23rd. Finally, StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Saturday, September 14th. Six analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and a consensus target price of $174.31.

Get Our Latest Report on JNJ

Johnson & Johnson Stock Up 0.6 %

Shares of NYSE:JNJ traded up $0.95 on Friday, reaching $161.46. The company had a trading volume of 5,253,459 shares, compared to its average volume of 7,039,524. Johnson & Johnson has a 52-week low of $143.13 and a 52-week high of $168.85. The firm’s 50 day simple moving average is $162.59 and its 200-day simple moving average is $154.48. The firm has a market capitalization of $388.58 billion, a PE ratio of 10.07, a PEG ratio of 2.65 and a beta of 0.52. The company has a current ratio of 1.07, a quick ratio of 0.85 and a debt-to-equity ratio of 0.44.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last posted its quarterly earnings data on Wednesday, July 17th. The company reported $2.82 earnings per share for the quarter, topping analysts’ consensus estimates of $2.71 by $0.11. The firm had revenue of $22.45 billion during the quarter, compared to analysts’ expectations of $22.33 billion. Johnson & Johnson had a return on equity of 36.60% and a net margin of 46.34%. The business’s quarterly revenue was up 4.3% on a year-over-year basis. During the same quarter last year, the firm earned $2.80 EPS. As a group, analysts expect that Johnson & Johnson will post 10 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, September 10th. Shareholders of record on Tuesday, August 27th were given a dividend of $1.24 per share. The ex-dividend date of this dividend was Tuesday, August 27th. This represents a $4.96 dividend on an annualized basis and a yield of 3.07%. Johnson & Johnson’s dividend payout ratio is currently 30.92%.

Johnson & Johnson Company Profile

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.

Recommended Stories

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).